Is it time to include screening for neonatal alloimmune thrombocytopenia in the general antenatal health care programme?

Transfusion and Apheresis Science

Volumn 38, Issue 3, 2008, Pages 183-188

  Kjeldsen Kragh, Jens ^a   Husebekk, Anne ^b,c   Killie, Mette Kjær ^b,c   Skogen, Bjørn ^b,c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN PLATELET ANTIGEN 1A; THROMBOCYTE ANTIBODY; THROMBOCYTE ANTIGEN;

ALLOIMMUNITY; ANTIBODY DETECTION; ANTIBODY SCREENING; ARTICLE; CESAREAN SECTION; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; EDUCATION PROGRAM; HUMAN; NEWBORN; NEWBORN ALLOIMMUNE THROMBOCYTOPENIA; NEWBORN DISEASE; NEWBORN SCREENING; NORWAY; PRENATAL DIAGNOSIS; PRENATAL SCREENING; RISK REDUCTION; SCREENING TEST; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 44949233538     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2008.04.010     Document Type: Article

References (32)

1. Blanchette V.S., Johnson J., and Rand M. The management of alloimmune neonatal thrombocytopenia. Baillieres Best Pract Res Clin Haematol. 13 (2000) 365-390
2. Kaplan C., Daffos F., Forestier F., Morel M.C., Chesnel N., and Tchernia G. Current trends in neonatal alloimmune thrombocytopenia: diagnosis and therapy. In: Kaplan-Gouet C., Schlegel N., Salmon C., and McGregor J. (Eds). Platelet immunology: fundamental and clinical aspects (1991), Lolloque INSERM/John Libbey Eurotext, Paris
3. Mueller-Eckhardt C., Kiefel V., Grubert A., Kroll H., Weisheit M., Schmidt S., et al. 348 Cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1 (1989) 363-366
4. Muller J.Y., Reznikoff-Etievant M.F., Patereau C., Dangu C., and Chesnel N. Thrombopenies neo-natales allo-immunes. Etude clinique et biologique de 84 cas. Presse Med 14 (1985) 83-86
5. Spencer J.A., and Burrows R.F. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol 41 (2001) 45-55
6. de Moerloose P., Boehlen F., Extermann P., and Hohfeld P. Neonatal thrombocytopenia: incidence and characterization of maternal antiplatelet antibodies by MAIPA assay. Br J Haematol 100 (1998) 735-740
7. Doughty H.A., Murphy M.F., Metcalfe P., and Waters A.H. Antenatal screening for fetal alloimmune thrombocytopenia: the results of a pilot study. Br J Haematol 90 (1995) 321-325
8. Dreyfus M., Kaplan C., Verdy E., Schlegel N., Durand-Zaleski I., and Tchernia G. Frequency of immune thrombocytopenia in newborns: a prospective study. Immune thrombocytopenia working group. Blood 89 (1997) 4402-4406
9. Durand-Zaleski I., Schlegel N., Blum-Boisgard C., Uzan S., Dreyfus M., and Kaplan C. Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs. Immune thrombocytopenia working group. Am J Perinatol 13 (1996) 423-431
10. Maslanka K., Guz K., and Zupanska B. Antenatal screening of unselected pregnant women for HPA-1a antigen, antibody and alloimmune thrombocytopenia. Vox Sang 85 (2003) 326-327
11. Williamson L.M., Hackett G., Rennie J., Palmer C.R., Maciver C., Hadfield R., et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood 92 (1998) 2280-2287
12. Radder C.M., Brand A., and Kanhai H.H. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it?. Vox Sang 84 (2003) 318-325
13. Murphy M.F., Williamson L.M., and Urbaniak S.J. Antenatal screening for fetomaternal alloimmune thrombocytopenia: should we be doing it?. Vox Sang 83 Suppl. 1 (2002) 409-416
14. Turner M.L., Bessos H., Fagge T., Harkness M., Rentoul F., Seymour J., et al. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion 45 (2005) 1945-1956
15. Killie M.K., Kjeldsen-Kragh J., Randen I., Skogen B., and Husebekk A. Evaluation of a new flow cytometric HPA 1a screening method. A rapid and reliable tool for HPA 1a screening of blood donors and pregnant women. Transfus Apher Sci 30 (2004) 89-92
16. Kjeldsen-Kragh J., Killie M.K., Tomter G., Golebiowska E., Randen I., Hauge R., et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 110 (2007) 833-839
17. Klinge J., Auberger K., Auerswald G., Brackmann H.H., Mauz-Korholz C., and Kreuz W. Prevalence and outcome of intracranial haemorrhage in haemophiliacs -- a survey of the paediatric group of the German society of thrombosis and haemostasis (GTH). Eur J Pediatr 158 Suppl. 3 (1999) S162-S165
18. George J.N., Woolf S.H., Raskob G.E., Wasser J.S., Aledort L.M., Ballem P.J., et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American society of hematology. Blood 88 (1996) 3-40
19. Looney C.B., Smith J.K., Merck L.H., Wolfe H.M., Chescheir N.C., Hamer R.M., et al. Intracranial hemorrhage in asymptomatic neonates: prevalence on MR images and relationship to obstetric and neonatal risk factors. Radiology 242 (2007) 535-541
20. L'Abbe D., Tremblay L., Filion M., Busque L., Goldman M., Decary F., et al. Alloimmunization to platelet antigen HPA-1a (PIA1) is strongly associated with both HLA-DRB3*0101 and HLA-DQB1*0201. Human Immunol 34 (1992) 107-114
21. .
22. Blanchette V.S., Chen L., de Friedberg Z.S., Hogan V.A., Trudel E., and Decary F. Alloimmunization to the PlA1 platelet antigen: results of a prospective study. Br J Haematol 74 (1990) 209-215
23. Burrows R.F., and Kelton J.G. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med 329 (1993) 1463-1466
24. Davoren A., McParland P., Crowley J., Barnes A., Kelly G., and Murphy W.G. Antenatal screening for human platelet antigen-1a: results of a prospective study at a large maternity hospital in Ireland. BJOG 110 (2003) 492-496
25. Mueller-Eckhardt C., Mueller-Eckhardt G., Willen-Ohff H., Horz A., Kuenzlen E., O'Neill G.J., et al. Immunogenicity of and immune response to the human platelet antigen Zwa is strongly associated with HLA-B8 and DR3. Tissue Antigens 26 (1985) 71-76
26. Panzer S., Auerbach L., Cechova E., Fischer G., Holensteiner A., Kitl E.M., et al. Maternal alloimmunization against fetal platelet antigens: a prospective study. Br J Haematol 90 (1995) 655-660
27. Reznikoff-Etievant M.F., Kaplan C., Muller J.Y., Daffos F., and Forestier F. Allo-immune thrombocytopenias, definition of a group at risk: a prospective study. Curr Stud Hematol Blood Transfus (1988) 119-124
28. Sainio S., Jarvenpaa A.L., Renlund M., Riikonen S., Teramo K., and Kekomaki R. Thrombocytopenia in term infants: a population-based study. Obstet Gynecol 95 (2000) 441-446
29. Uhrynowska M., Maslanka K., and Zupanska B. Neonatal thrombocytopenia: incidence, serological and clinical observations. Am J Perinatol 14 (1997) 415-418
30. Uhrynowska M., Niznikowska-Marks M., and Zupanska B. Neonatal and maternal thrombocytopenia: incidence and immune background. Eur J Haematol 64 (2000) 42-46
31. Killie M.K., Kjeldsen-Kragh J., Husebekk A., Skogen B., Olsen J.A., and Kristiansen I.S. Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia. BJOG 114 (2007) 588-595
32. Killie M.K., Kjeldsen-Kragh J., Skogen B., and Husebekk A. Maternal anti-HPA1a antibody level as predictive value in neonatal alloimmune thrombocytopenic purpura (NAITP). Blood 104 (2004) 570a-571a